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Supplemental landiolol administration (20 or 40 μg kg−1 min−1) effectively diminished harmful hemodynamic
changes during bronchoscopic endotracheal suctioning compared to normal saline. However, inappropriate use
of landiolol (i.e., failure of evaluating factors that influence hemodynamic changes) may iatrogenically further
complicate pathophysiology, and relatively higher doses of landiolol may be dangerous. We recommend that
landiolol should not be routinely used to control cardiovascular responses during bronchoscopic endotracheal
suctioning in the intensive care unit. Careful evaluation of factors influencing hemodynamic changes and close
monitoring of the patient are mandatory following landiolol administration. Furthermore, a lower initiation dose
is recommended.
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We read the article Landiolol reduces hemodynamic res-
ponses to bronchoscopy-assisted suctioning in intubated
ICU patients by Tochikubo et al. with great interest [1].
The authors prospectively conducted a double-blind con-
trol study using a cross-over design to evaluate the pro-
tective effects of landiolol against cardiovascular responses
during bronchoscopic endotracheal suctioning. Because
there is a word limitation for publishing the current
manuscript as a Letter to the Editor, not Original Article,
we assume that authors were not able to provide sufficient
data. Therefore, we would like to clarify the details of the
current great literature through this letter.
We recently reported our clinical experience with the
use of landiolol hydrochloride for conservative mana-
gement of blunt aortic injury (BAI) [2]. In BAI patients, ag-
gressive blood pressure management along with decreased
heart rate and contractility with beta-blocker therapy is
critical for decreasing aortic wall tension, and it is essential
during nonoperative management or during the treatment
period leading up to delayed surgery. Heart rate is in-
fluenced by several factors such as hypovolemia due
to massive bleeding, pain, anxiety, fever, and sympathetic
activation in trauma patients. Therefore, we not only clari-
fied the significance of using landiolol but also emphasized* Correspondence: hifumitoru@gmail.com
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changes and close monitoring of vital signs are mandatory
during beta-blocker administration.
Although details regarding the patient’s baseline char-
acteristics remain unknown, it appeared that Tochikubo
et al. [1]. did not adjust several factors that influence
hemodynamic changes such as hypovolemia, pain, fever,
and sympathetic activation in each group. We are greatly
concerned that the inappropriate use of landiolol (i.e.,
failure of evaluating factors that influence hemodynamic
changes) may iatrogenically further complicate patient’s
pathophysiology.
Tochikubo et al. [1] mentioned that endotracheal
suctioning stimulus induces undesirable cardiovascular
sympathetic responses and cited literature conducted by
Jongerden et al. [3]; however, Jongerden et al. concluded
that changes in heart rate, mean arterial pressure, and
oxygen saturation were mild both during and after use
of closed and open suction systems without the admi-
nistration of landiolol [3]. When control of cardiovascular
responses during bronchoscopic endotracheal suctioning
is required, transient deeper sedation and analgesia inclu-
ding local anesthesia in the trachea during the procedure,
instead of administering beta-blockers, is considered a
simple first-line strategy.
Moreover, additional indications of landiolol use for
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fore, the Japanese Circulation Society published a state-
ment for the appropriate use of landiolol [5]. These
guidelines recommend initiation with a lower dose of
landiolol (1 μg kg−1 min−1) for patients with impaired
left ventricular function because the clinical safety for
those who severely impaired left ventricular function
has not been evaluated. Tochikubo et al. used 20 or
40 μg kg−1 min−1 landiolol to control cardiovascular
responses during bronchoscopic endotracheal suction-
ing in the current study; therefore, we were concerned
regarding the safety of landiolol use at these dosages.
In fact, after bronchoscopic endotracheal suctioning,
patients in the landiolol groups exhibited decreased
heart rate and systolic blood pressure from baseline.
Although patients with severely impaired left ventricular
function appeared to be excluded in the current study, we
recommend that they provide the inclusion and exclusion
criteria.
In conclusion, we recommend that landiolol should
not be routinely used for control of cardiovascular res-
ponses during bronchoscopic endotracheal suctioning
in the ICU patients. Careful evaluation of factors that
influence hemodynamic changes and close monitor-
ing of vital signs are mandatory during landiolol ad-
ministration. In addition, a lower initiation dose is
recommended.
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